{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:05:04Z","timestamp":1774260304354,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cutaneous melanoma (CM) is a significant health concern because of its high metastatic potential. Gene Expression Profile (GEP) testing, particularly the 31\u2010GEP test (DecisionDx\u2010Melanoma), has been increasingly used for risk stratification in CM patients. This study aimed to evaluate the clinical utility and performance of the 31\u2010GEP test in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with CM who underwent 31\u2010GEP testing from August 2014 to August 2022 at our institution were identified through searches of electronic health records. The study analyzed the influence of 31\u2010GEP testing on clinical decision\u2010making related to sentinel lymph node biopsy (SLNB), medical oncology referral, and postdiagnosis surveillance. Kaplan\u2013Meier curves and Cox proportional hazard models were used to elucidate the test's performance, focusing on relapse\u2010free survival (RFS) and melanoma\u2010specific survival (MSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 65 CM patients. Dermatologists ordered more than 80% of 31\u2010GEP tests. In 81.5% of cases, 31\u2010GEP results did not alter standard clinical management. SLNB decisions were unaffected in 92% of patients with pre\u2010SLNB 31\u2010GEP results. Among patients with stage I\u2010IIA melanoma, 25% of those with high\u2010risk 31\u2010GEP results were referred to medical oncology. Contrary to expectations, the rate of nodal metastasis was higher in low\u2010risk than in high\u2010risk 31\u2010GEP cases. Survival analysis showed overlapping RFS and MSS curves between different 31\u2010GEP classes, suggesting limited prognostic value.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The 31\u2010GEP test has a limited impact on clinical management decisions and shows limited prognostic value.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.17440","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T18:24:52Z","timestamp":1724005492000},"page":"563-570","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["31\u2010GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8764-1731","authenticated-orcid":false,"given":"Ani","family":"Pazhava","sequence":"first","affiliation":[{"name":"Department of Dermatology Mayo Clinic  Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong\u2010hun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic  Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-9163","authenticated-orcid":false,"given":"Frank Z.","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic  Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Pittelkow","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic  Scottsdale AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Melanoma of the Skin \u2013 cancer stat facts.SEER. Accessed September 15 2022.https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00821-8"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/35020115"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01101-y"},{"issue":"4","key":"e_1_2_6_6_1","first-page":"292","article-title":"CP\u2010GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?","volume":"158","author":"Quattrocchi E","year":"2023","journal-title":"Ital J Dermatol Venerol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.11.004"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3316"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","unstructured":"Castle Biosciences Inc.Castle Biosciences reports fourth quarter and full\u2010year 2022 results.2023. Accessed February 28 2023.https:\/\/ir.castlebiosciences.com\/news\/news-details\/2023\/Castle-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2022-Results\/default.aspx","DOI":"10.1016\/j.fopow.2023.02.013"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6819"},{"key":"e_1_2_6_11_1","unstructured":"Treatment by cancer type.NCCN. Accessed December 25 2023.https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.6.7"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02362"},{"key":"e_1_2_6_14_1","unstructured":"Melanoma Institute Australiaa Dev Gayan Jayaweera 2020 03 17 using Nomogram SL. Melanoma risk assessment tool. Accessed August 29 2022.https:\/\/www.melanomarisk.org.au\/ThinMelForm"},{"key":"e_1_2_6_15_1","unstructured":"Genetic testing for oncology. Accessed December 18 2023.https:\/\/www.cms.gov\/medicare\u2010coverage\u2010database\/view\/lcd.aspx?lcdid=39667&ver=9&keyword=&keywordType=starts&areaId=all&docType=NCA CAL NCD MEDCAC TA MCD 6 3 5 1 F P&contractOption=all&sortBy=updated&bc=1"},{"key":"e_1_2_6_16_1","volume-title":"Staging work\u2010up and surveillance of cutaneous melanoma (UpToDate: topic 7621, Version 40.0)","author":"Buzaid AC"},{"key":"e_1_2_6_17_1","volume-title":"Evaluation and management of regional nodes in primary cutaneous melanoma (Topic 7616 Version 49.0)","author":"Gershenwald JE"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2131"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00926.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.05.012"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1202"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0127"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11231-3"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:27:30Z","timestamp":1747675650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/ijd.17440"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17440","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,18]]},"assertion":[{"value":"2024-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}